Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19

Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19

FORT COLLINS -- Cytocom, Inc. announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety... Read More

Thursday March 18, 2021 0 comments Tags: Fort Collins, Cytocom, CYTO-205, Michael Handley, FDA

Cytocom in proposed merger with Cleveland BioLabs after SEC filing

Cytocom in proposed merger with Cleveland BioLabs after SEC filing

FORT COLLINS/ BUFFALO, N.Y. -- New York-based Cleveland BioLabs, Inc. (NASDAQ: CBLI), a biopharmaceutical company developing novel approaches to activate the immune system, filed a registration... Read More

Thursday February 18, 2021 0 comments Tags: Fort Collins, Cytocom, Cleveland BioLabs, Michael Handley

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19

FORT COLLINS -- Cytocom, Inc. today provided an update regarding its CYTO-200 portfolio of clinical programs. Cytocom said it has submitted an Investigational New Drug (IND) application with... Read More

Tuesday February 16, 2021 0 comments Tags: Fort Collins, Cytocom, COVID-19, CYTO-205, Michael Handley

Marizyme appoints two new board members

Marizyme appoints two new board members

FORT COLLINS -- Marizyme, Inc., a publicly traded (OTC:MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, today... Read More

Monday December 17, 2018 0 comments Tags: Fort Collins, Marizyme, James Sapirstein, Terry Brostowin, Michael Handley

CHD Bioscience partners with Dr. Reddy’s Labs for global licensing of DFA-02

CHD Bioscience partners with Dr. Reddy’s Labs for global licensing of DFA-02

FORT COLLINS -- India-based Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Fort Collins-based CHD Bioscience Inc. , a privately-held biopharmaceutical company, today... Read More

Thursday July 27, 2017 0 comments Tags: Fort Collins, CHD Bioscience, Dr. Reddy's Laboratories, Michael Handley, DFA-02

CHD Bioscience: Tests show Veriox effective against healthcare associated infections

CHD Bioscience: Tests show Veriox effective against healthcare associated infections

FORT COLLINS -- CHD Bioscience announced that preliminary independent testing conducted by ATS Labs in Minnesota has demonstrated the company's lead product -- Veriox -- to be effective against... Read More

By: InnovatioNews Thursday October 10, 2013 0 comments Tags: CHD Bioscience, CRE bacteria, Fort Collins, Michael Handley, VERIOX